antimycin A

Antimycin A binds to the Qi site of Complex III (ubiquinol-cytochrome c reductase), preventing the transfer of electrons from cytochrome b to cytochrome c1 in the mitochondrial electron transport chain. This blockade halts the flow of electrons down the ETC, preventing the pumping of protons at Complex III and collapsing the proton gradient needed for ATP synthase (Complex V) to generate ATP via oxidative phosphorylation. As a classic ETC Complex III inhibitor, it is grouped with other inhibitors used to map out electron flow in biochemistry: Complex I inhibitors (rotenone, amytal), Complex III inhibitor (antimycin A), Complex IV inhibitors (cyanide, azide, CO), and ATP synthase inhibitors (oligomycin). Unlike uncouplers (e.g., 2,4-DNP, thermogenin), which dissipate the proton gradient without blocking electron transport, antimycin A directly halts electron flow itself, leading to a buildup of reduced electron carriers (NADH, reduced cytochromes) proximal to the block. This causes cellular ATP depletion, increased reactive oxygen species (ROS) generation, and can trigger apoptosis via mitochondrial permeability transition pore opening—making antimycin A a valuable tool in apoptosis and mitochondrial function research (e.g., inducing controlled ROS production in cell biology experiments). Clinically, antimycin A is not used therapeutically in humans due to its high toxicity; it has historical use as a piscicide (fish poison) for aquatic pest control and as an agricultural fungicide/insecticide. For board exams, the key testable concept is distinguishing antimycin A's mechanism (electron transport blocker at Complex III) from uncouplers and ATP synthase inhibitors, understanding the resulting biochemical consequences (cessation of oxygen consumption, ATP depletion, and back-up of the proton gradient), and its classification alongside cyanide and rotenone in ETC toxicology questions.